AbbVie’s Rinvoq hits targets in atopic dermatitis trial
The JAK inhibitor significantly improved skin clearance and reduced itch
Read More
Tag: dermatitis
Investigational atopic dermatitis drug hits late-stage endpoints
There is currently a “critical need” for additional treatment options for atopic dermatitis.
Read More
Dupixent hits endpoints in paediatric trial
33% of patients who received Dupixent every four weeks achieved clear or almost clear skin.
Read More
Pfizer announces positive dermatitis therapy phase III results
The company’s Janus kinase 1 has met all co-primary and secondary endpoints in a pivotal Phase III study.
Read More
Four new medicines available via NHS Scotland
The Scottish Medicines Consortium has cleared funds for use of four new medicines by NHS Scotland, including Sanofi’s biologic Dupixent for dermatitis.
Read More
GSK sells psoriasis/dermatitis therapy to Dermavant
GlaxoSmithKline has sold rights to an experimental therapy being developed for psoriasis and dermatitis to Dermavant in a deal worth $330 million.
Read More
EMA to review Regeneron, Sanofi’s atopic dermatitis biologic
European regulators have accepted for review Regeneron and Sanofi’s application to market Dupixent for the treatment of certain adults with atopic dermatitis.
Read More
Sanofi/Regeneron’s dupilumab hits targets in dermatitis trial
Sanofi and Regeneron’s experimental therapy dupilumab has hit primary and secondary targets in a late-stage trial assessing its effectiveness in patients with poorly controlled atopic dermatitis.
Read More
- Laigo Bio completes final close of €17m seed financing round
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
- Ondine’s Steriwave phase 3 trial reaches 93% enrolment milestone
- Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
